Investment Case for a Comprehensive Package of Interventions against Hepatitis B in China
Shevanthi Nayagam(Imperial College London), Timothy B. Hallett(Imperial College London), Lance E. Rodewald, Yanping Qiu, Yuhan Wang, Mark Thursz(Imperial College Healthcare NHS Trust), Hong Zhuang, Daniel Low‐Beer(World Health Organization), Nick Walsh(World Health Organization Regional Office for the Americas), Weiwei Hou(National Health and Family Planning Commission), G. Zhang, Ju Tsun Chang, Polin Chan(Western University), Fabio Scano(World Health Organization), Xuexuan Wang(Unknown), WU Ai-ling, Dong lixia -, Elisa Sicuri(Barcelona Institute for Global Health), Long Wei(Palace Museum), Bernhard Schwartländer(World Health Organization), Kehan Zhao, Yue Xiao(National Health and Family Planning Commission), Bingrun Sui, Jidong Jia(National Clinical Research Center for Digestive Diseases)
Cited by 10
Related Papers
Association between an MHC Class II Allele and Clearance of Hepatitis B Virus in the Gambia
|New England Journal of Medicine|1995|439
HIV Treatment as Prevention: Systematic Comparison of Mathematical Models of the Potential Impact of Antiretroviral Therapy on HIV Incidence in South Africa
|PLoS Medicine|2012|406
Requirements for global elimination of hepatitis B: a modelling study
|The Lancet Infectious Diseases|2016|384